CorMedix Inc

CRMD Healthcare Biotechnology

CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024.

Revenue
+156.5%
EPS
+13.8%
Free cash flow
+185.9%

Quarter to June 2026, against a year earlier

5.30 0.07 +1.34%
Market cap
$407.6M
P/E
2.2×
Fwd P/E
11.5×
Dividend yield
—
F-score
n/a
Altman Z
2.15
Beneish M
12.80
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
3 4 4 3 4 5 4 — — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 5.26
Altman Z-Score
(1.85) (20.62) (12.34) 7.43 18.12 11.40 7.80 — 4.93 2.15
P/S ratio
289.71 88.72 267.37 620.64 887.19 897.28 2,574.09 — 10.96 2.69
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 4.85
Altman Z″-Score (non-manufacturers)
(15.45) (48.70) (36.41) (16.91) (3.10) 2.06 (3.87) — (3.52) 3.07
Beneish M-Score
— (2.99) (0.03) — — 11.52 — — — 12.80
P/Operating CF
(9.99) (4.02) (15.96) (45.26) (35.77) (29.20) (27.35) — (84.93) 8.87
P/B ratio
3.64 4.06 23.29 7.44 4.80 2.73 3.06 — 5.63 2.07
EV/Sales
198.96 51.82 240.22 519.95 696.40 558.04 1,683.43 — 9.79 2.68
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 5.04
EV/FCF
(2.00) (0.59) (4.35) (9.76) (7.54) (4.72) (4.48) — (8.39) 4.83
Current Ratio
5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39 2.11
Net Debt/EBITDA
0.82 0.37 0.44 1.38 1.69 2.21 1.92 1.56 2.36 (0.02)
Debt/Equity
0.00 0.00 1.24 0.00 0.02 0.01 0.01 0.00 0.00 0.36
ROE
(95.10%) (264.01%) (442.49%) (304.66%) (64.91%) (52.72%) (50.40%) (74.02%) (23.17%) 66.56%
ROA
(83.53%) (186.71%) (166.23%) (180.27%) (55.92%) (47.71%) (45.35%) (64.32%) (17.85%) 34.51%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (42.38%) 23.34%
Return on Tangible Assets
(138.37%) (458.89%) (242.59%) (184.13%) (49.91%) (45.07%) (54.15%) (66.28%) (21.72%) 82.04%
Average Days of Receivables
19.54 71.05 9.26 0.00 5.19 86.80 0.00 — 433.70 200.51
Earnings Yield
(37.43%) (115.09%) (25.58%) (9.33%) (10.23%) (16.26%) (17.70%) — (4.07%) 19.00%
Free Cash Flow Yield
(34.39%) (98.34%) (20.67%) (8.58%) (10.40%) (13.18%) (14.60%) — (10.64%) 20.62%
Free Cash Flow per Share
(2.94) (2.61) (1.33) (0.62) (0.77) (0.60) (0.61) (0.76) (0.86) 2.40
Book value per Share
2.35 0.65 0.28 0.98 1.55 1.67 1.37 1.38 1.44 5.63
Free Cash Flow
(22.32) (28.74) (23.75) (15.09) (22.08) (22.58) (24.58) (38.74) (50.73) 172.79
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 5.55
Other line items

Show all line items

Columns are period end dates